EGFR and pancreatic ductal adenocarcinoma: Moreover, clinical observations indicate that pancreatic ductal adenocarcinoma may activate alternative signaling pathways to circumvent EGFR inhibition, further reducing the efficacy of therapies that target only EGFR (Qian et al. 2020).